Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
February 3, 2015 4:05 PM ESTRevenues of $184.4 Million Adjusted Diluted EPS of $0.40, and Diluted EPS of $0.32 myRisk Hereditary Cancer Revenues of $85.1 Million BRACAnalysis CDx Approved by the FDA Tumor BRACAnalysis CDx Granted European CE Marking Approval Company Revises Fiscal Year 2015 Financial Guidance; Provides Fiscal 3Q15 Financial Guidance
SALT LAKE CITY, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN) today announced financial results for its fiscal second-quarter and six months ended December 31, 2014, provided an update on recent business highlights,... More
